Pfizer's Xeljanz (tofacitinib citrate) Receives EC's Approval for the Treatment of Active Polyarticular JIA & Juvenile PsA
Shots:
- The approval is based on a P-III study which includes 2 phases i.e.- run-in & withdrawal phase evaluating efficacy & safety of tofacitinib (5mg tablet or mg/mL oral solution- BID) in 398 patients aged ≥2yrs. with polyarticular JIA & juvenile PsA who have had an inadequate response to previous therapy with DMARDs for 44wks.
- The study met its 1EPs i.e- patients achieved an ACR30 response at the end of the run-in phase; occurrence of disease flare (31% vs 55%) @44wks. & efficacy in juvenile PsA subtype population was consistent with polyarticular JIA
- Xeljanz (11mg- qd) has also received EC’s approval for active PsA who have had an inadequate response/intolerance to methotrexate or other DMARDs
Ref: Businesswire | Image: Wall Street Journal
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com